A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study
Launched by INVENIO IMAGING INC. · Jun 20, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the ON-SITE study, is looking at a new way to quickly detect lung cancer during lung biopsy procedures. Instead of sending tissue samples to a lab for traditional testing, this study uses a special laser imaging system combined with artificial intelligence (AI) right in the procedure room. The AI helps doctors spot signs of cancer in lung tissue or nearby lymph nodes faster than usual. This could speed up diagnosis and help guide treatment sooner.
The study is open to adults 22 years and older who are scheduled for lung biopsies because their doctor suspects they might have lung cancer. Participants will undergo one of several types of biopsies, which involve collecting small samples from lung nodules or lymph nodes using different tools. If you join, the new imaging and AI technology will be used during your routine biopsy procedure to analyze the tissue immediately, but the procedure itself will be the same as usual. This study is still recruiting participants, and it is important that you are able to safely undergo the biopsy and understand the consent form before joining. Prisoners and those deemed unsuitable by the doctor cannot participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The patient or legal guardian is willing and able to understand, sign and date the Ethics committee approved study specific Informed Consent Form.
- • 2. The patient is 22 years of age or older.
- • 3. The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion.
- • 4. The patient can tolerate the clinical procedure as indicated.
- Exclusion Criteria:
- • 1. Patient is a prisoner.
- • 2. The participant, in the judgment of the Investigator, may be inappropriate for the intended study procedures
About Invenio Imaging Inc.
Invenio Imaging Inc. is a medical technology company specializing in the development and commercialization of advanced imaging solutions designed to improve the diagnosis and treatment of neurological conditions. Leveraging cutting-edge artificial intelligence and proprietary imaging algorithms, Invenio Imaging aims to enhance clinical decision-making and patient outcomes by providing more accurate and timely insights for healthcare professionals. The company is committed to innovation in neuroimaging to support research and clinical applications worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronx, New York, United States
New York, New York, United States
Jacksonville, Florida, United States
Chapel Hill, North Carolina, United States
San Diego, California, United States
Grand Rapids, Michigan, United States
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported